The disease groups that comprise OneOncology’s clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology; and medical director for clinical pathways, OneOncology. He spoke with Evidence-Based Oncology™ (EBO) during the 11th Annual of Patient-Centered Oncology Care® (PCOC) meeting, held in Nashville, Tennessee.
EBO: What is the role of disease groups in the OneOncology clinical pathways program?
Arrowsmith: Our idea of pathways is to have them really be bottom up and then top down. We’ve instituted disease groups that cover about 90% of patients with cancer. They have experts from each of the 15 practices in OneOncology, and work collaboratively to develop the pathways to develop best practices for treatment of cancer for the majority of patients. Of course, there’ll be some patients [for whom] being off pathway is the right thing to do, but this is the expert consensus. It then comes up to the clinical team at OneOncology, who does clerical work and other work, and then helps push that information back to every doctor practicing across the practices in OneOncology.
EBO: How do member practices of OneOncology work with these clinical pathways day to day?
Arrowsmith: Our pathways process is relatively new. OneOncology is a new organization, and we’ve been working on pathways diligently for about 18 months. The main way that we see providers working with the pathways will be through a tool called Flatiron Assist. The OneOncology conference [held November 11-13 served] as the big rollout of that tool. That’s a clinical decision support tool developed in conjunction with Flatiron Health, who is our [electronic medical record] partner. Based on the intellectual work done by the disease groups [the tool] will guide clinicians to using a pathway concordant regimen, whenever they order. That can be customized by OneOncology based on value-based care, clinical trials, or other attributes that are unique to our practices.
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More